Incremental Cost of Switching to Extended Half-life (EHL) Coagulation Factor Products to Treat Hemophilia Among 15 Million Commerically Insured Members

Background

- Extended Half-life (EHL) coagulation factor FVIII and FIX products are now approved by the FDA.
- In this study, we examined the practical application of the Athenian Health Network (ATHN) dataset, a large, longitudinal dataset of commercially insured patients, and the National Hemophilia Foundation’s Medical and Scientific Advisory Council (MASAC) Recommendations concerning prophylaxis.

Methods

- We analyzed data from 15 million commercially insured members, collected through the ATHN database.
- We focused on members with hemophilia A (n = 131,367) and hemophilia B (n = 12,435).
- We evaluated the incremental cost of switching to EHL products.
- We measured the proportion of members prescribed EHL products.
- We assessed the impact of switchers on factor cost and units.

Results

- We found that the proportion of hemophilia A patients prescribed an EHL FVIII increased from 13% at baseline to 21% at the end of the analysis period.
- The proportion of hemophilia B patients prescribed an EHL FIX increased from 7% at baseline to 12% at the end of the analysis period.
- The proportion of members using EHL products by time intervals is as follows:
  - First quarter: 9% of hemophilia A members and 4% of hemophilia B members.
  - Second quarter: 12% of hemophilia A members and 6% of hemophilia B members.
  - Third quarter: 13% of hemophilia A members and 7% of hemophilia B members.
  - Fourth quarter: 14% of hemophilia A members and 8% of hemophilia B members.

Conclusions

- In this paper, we evaluated the incremental cost of switching to EHL factor products to both hemophilia A and B patients with commercially insured health plans. We found that switching to EHL products resulted in lower costs for hemophilia A and B patients.

References

- The Athenian Health Network database.
- The National Hemophilia Foundation’s Medical and Scientific Advisory Council (MASAC) Recommendations concerning prophylaxis.
- The ATHN dataset can be accessed at www.athennetwork.org.